A major collaboration between Eli Lilly and Insilico Medicine signals growing momentum for AI-driven drug discovery, with multiple therapies set to progress towards global commercialisation.
Eli Lilly and Company has signed a deal worth up to US$2.75 billion with Insilico Medicine to develop and commercialise a pipeline of drugs discovered using artificial intelligence.
The agreement includes an upfront payment of US$115 million to Insilico, with additional milestone payments tied to development, regulatory approval and commercial performance, alongside royalties on future sales.
The partnership builds on an existing relationship between the two companies, which began in 2023 through an AI-focused software collaboration. Under the new agreement, Lilly will receive exclusive global rights to develop, manufacture and commercialise a portfolio of novel oral therapeutics currently in preclinical development.
The companies have not publicly disclosed the number of licensed assets, specific targets or disease areas involved. Some reporting has suggested that a GLP-1-related asset may form part of the agreement, although this has not been confirmed.
AI accelerates drug discovery pipeline
Insilico has emerged as one of the leading players in AI-driven drug discovery, having developed at least 28 drug candidates using generative AI technologies — with nearly half already progressing through clinical stages.
The company’s platform leverages deep learning models to identify biological targets and design new molecules more efficiently than traditional discovery methods, significantly reducing research timelines.
Founder and CEO Alex Zhavoronkov said the collaboration reflects the growing role of AI in addressing complex disease pathways, while also acknowledging Lilly’s strengths in integrating biology, chemistry and automation at scale.
As part of the agreement, Insilico will also join Lilly’s Gateway Labs ecosystem, further embedding its AI capabilities within the pharmaceutical giant’s broader R&D infrastructure.
Strategic push into AI-enabled therapeutics
For Lilly, the deal represents a continued investment in AI as a core component of its drug discovery strategy. The company has increasingly positioned itself at the intersection of biotechnology and advanced computational science, seeking to accelerate the identification of new therapeutic candidates across multiple disease areas.
‘This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates,’ said Andrew Adams, Group Vice President of Molecule Discovery at Lilly, who described Insilico’s platform as a ‘powerful complement’ to the company’s clinical development expertise.
The partnership comes amid broader expansion efforts by Lilly, including a recently announced US$3 billion investment in China over the next decade, underscoring its global growth ambitions.
Implications for the future of drug development
The deal highlights a broader shift within the pharmaceutical industry, where AI is moving from experimental tool to commercial driver of drug pipelines.
By enabling faster target identification, molecule design and early-stage validation, AI platforms are increasingly seen as a way to reduce both the cost and time associated with bringing new therapies to market.
As these collaborations deepen, AI-enabled drug discovery is expected to play a growing role in shaping the next generation of therapeutics, particularly in areas of high unmet clinical need.
